AngioDynamics (Queensbury, New York) closed its $220 million acquisition of Rita Medical Systems (Fremont, California). Each share of Rita common stock was converted into the right to receive 0.1722 of a share of common stock of AngioDynamics and $0.515 in cash. The purchase, which includes assumption of roughly $3.3 million in Rita debt, was disclosed in November. “This business combination is about growth, leadership and long-term value creation. AngioDynamics now stands as a leader in serving the needs of interventional radiologists, surgeons and other medical specialties with a compelling product portfolio of exciting technologies,” said Eamonn Hobbs, president/CEO of AngioDynamics. AngioDynamics said Rita’s position in vascular access ports is an ideal fit with its Morpheus CT PICC and the vascular access port technology it bought from Medron (Salt Lake City) last May. AngioDynamics also noted its recently acquired irreversible electroporation (IRE) soft tissue ablation technology, expected for first sales in mid-2008, as complementing its local oncology therapies. AngioDynamics manufactures devices used for minimally invasive diagnosis and treatment of peripheral vascular disease.

Arrhythmia Research Technology (ART) reported that its subsidiary, Micron Products (both Fitchburg, Massachusetts) — a manufacturer of silver/silver chloride and conductive resin sensors used in disposable ECG, EKG and EEG monitoring and diagnostic electrodes — completed the purchase of Leominster Tool Company (Leominster, Massachusetts). “The addition of the new Leominster Tool division vertically integrates mold design and manufacturing with Micron’s sensor product line, with the custom injection molding of our New England Molders division and the product life cycle management of our Micron Integrated Technologies division,” said James Rouse, president/CEO of ART and Micron. ART said that the Leominster Tool division will function independently as a high-end mold design and manufacturing provider for the injection molding industry.

Boston Scientific (Natick, Massachusetts) reported completing the purchase of EndoTex Interventional Systems (Cupertino, California), as it had agreed to within the 90-day time frame following FDA approval of Endotex’s NexStent carotid stent system. Terms were not disclosed. The NexStent was FDA-approved in November and was studied in the CABERNET trial along with the Boston Scientific FilterWire EZ embolic protection system. Boston Scientific had been awaiting approval of its FilterWire system, which is designed to efficiently capture plaque that may dislodge during stent implantation, thereby reducing the risk of procedural-related stroke. “Combining the resources of these two organizations demonstrates Boston Scientific’s commitment to leadership in treating carotid artery disease,” said John Pedersen, president of the company’s Peripheral Interventions business. The NexStent is a laser-cut, nitinol stent with a rolled sheet design that enables one stent size to adapt to multiple diameters in tapered or non-tapered vessel configurations. Its self-sizing feature is intended to provide customization when treating lesions in the carotid arteries, while its closed-cell configuration is designed to increase lesion coverage and to provide a smooth inner lumen to help facilitate delivery and retrieval of ancillary devices. Boston Scientific first invested in EndoTex in July 2001 and at the time negotiated an exclusive option to buy the company, which makes less-invasive devices and specializes in carotid stent technology.

Dade Behring (Deerfield, Illinois) reported that it has signed a license agreement with Radboud University Nijmegen Medical Centre (RUNMC; Nijmegen, the Netherlands) granting Dade Behring with the exclusive rights for a new coagulation test called the Nijmegen Hemostasis Assay (NHA), anticipated by researchers at RUNMC to become accepted for testing a broad range of coagulation disorders. A research agreement was also signed granting Dade Behring with the rights to results from future NHA research and development performed by RUNMC. Hemostasis is a complex process in which multiple components regulate blood flow and clot formation. Coagulation, fibrinolysis and platelet aggregation are a part of this process. The NHA is viewed by researchers to be important because it could provide insight into the whole blood-clotting process — simultaneously in one test.

Conor Medsystems (Menlo Park, California) reported that the U.S. Federal Trade Commission has granted early termination of the Hart-Scott-Rodino waiting period for its acquisition by Johnson & Johnson (New Brunswick, New Jersey) and a wholly owned subsidiary of J&J. The transaction remains subject to other customary closing conditions, including approval of the transaction by Conor stockholders. Conor said the transaction is expected to close as promptly as possible after the satisfaction of those conditions and a special meeting of Conor stockholders, scheduled for Jan. 31. Conor develops controlled vascular drug delivery technologies, and has primarily focused on the development of drug-eluting stents to treat coronary artery disease.